# US 2010/0074922 A1 · Pneumococcal polysaccharide conjugate vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0074922 A1
- Document ID: US20100074922A1
- Status: Published application
- Kind: A1
- Application number: 12/570,266
- Filed: 2009-09-30
- Published: 2010-03-25
- Earliest claimed: 2005-12-22
- Assignees: Glaxosmithkline Biologicals SA
- Inventors: Ralph Leon Biemans; Nathalie Marie-Josephe Garcon; Philippe Vincent Hermand; Jan Poolman; Marcelle Paulette Van Mechelen
- Web page: https://patentgrep.com/patent/US20100074922A1

## CPC

- A61K 39/092: {Streptococcus}
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/14: Decongestants or antiallergics
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/555: {characterised by a specific combination antigen/adjuvant}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/575: {humoral response}
- A61K 2039/6031: {Proteins}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K 2039/6068: {Other bacterial proteins, e.g. OMP}
- A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]}
- A61K 2039/62: {characterised by the link between antigen and carrier}
- A61K 2039/627: {characterised by the linker}
- A61K 2039/70: {Multivalent vaccine}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.

## Claims

### Claim 1

A method of immunising a human host against disease caused by Streptococcus pneumoniae serotype 19A infection comprising the step of administering to the host an immunoprotective dose of a Streptococcus pneumoniae immunogenic composition comprising 9 or more capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, wherein the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197 but does not comprise capsular saccharide from serotype 19A.

### Claim 2 (depends on 1)

The method of claim 1 wherein the immunogenic composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid.

### Claim 3 (depends on 1)

The method of claim 1 wherein the serotype 19F capsular saccharide is the only saccharide in the immunogenic composition conjugated to diphtheria toxoid.

### Claim 4 (depends on 1)

The method of claim 1 wherein the immunogenic composition comprises serotype 19F capsular saccharide directly conjugated to the carrier protein.

### Claim 5 (depends on 1)

The method of claim 1 wherein the immunogenic composition comprises serotype 19F capsular saccharide conjugated to the carrier protein via a linker.

### Claim 6 (depends on 1)

The method of claim 1 wherein the immunogenic composition comprises serotype 19F capsular saccharide conjugated to the carrier protein or to the linker using CDAP chemistry.

### Claim 7 (depends on 1)

The method of claim 1 wherein the ratio of carrier protein to serotype 19F capsular saccharide in the immunogenic composition is between 5:1 and 1:5.

### Claim 8 (depends on 1)

The method of claim 1 wherein the average size of the serotype 19F capsular saccharide in the immunogenic composition is above 100 kDa.

### Claim 9 (depends on 1)

The method of claim 1 wherein the dose of the serotype 19F saccharide conjugate in the immunogenic composition is between 1 and 10 μg of saccharide.

### Claim 10 (depends on 1)

The method of claim 1 wherein the immunogenic composition comprises 2 different carrier proteins.

### Claim 11 (depends on 1)

The method of claim 1 wherein one or more or all carrier proteins in the immunogenic composition is selected from the group consisting of DT, CRM 197, TT, Fragment C, dPly, PhtA, PhyB, PhtD, PhtE, PhtDE, OmpC, PorB and Haemophilus influenzae Protein D.

### Claim 12 (depends on 1)

The method of claim 1 wherein the immunogenic composition comprises capsular saccharide 18C conjugated to tetanus toxoid.

### Claim 13 (depends on 1)

The method of claim 1 wherein the immunogenic composition comprises capsular saccharide 18C conjugated to tetanus toxoid, wherein 18C is the only capsular saccharide in the composition conjugated to tetanus toxoid.

### Claim 14

A Streptococcus pneumoniae immunogenic composition comprising 9 or more capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, wherein the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, but does not comprise capsular saccharide from serotype 19A, wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.
